Latest Conference Articles

Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate Cancer

Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Open Source System Debuts for EHR Data Sharing

A consortium of cancer care institutions released details on a prototype system designed to link electronic health record systems to provide a source of real-world patient information to guide research and improve cancer treatment.

New Strategies Needed for TKI Resistance in EGFR+ Lung Cancer

The development of tyrosine kinase inhibitors has revolutionized the treatment of EGFR-mutant non–small cell lung cancer in recent years, but new strategies are needed to overcome resistance mechanisms that promote disease recurrence.

Apalutamide Extends Survival in Metastatic Castration-Sensitive Prostate Cancer

Adding apalutamide to androgen deprivation therapy (ADT) reduced the risk of the death by 33% in patients with metastatic castration-sensitive prostate cancer compared with ADT alone.

Frontline Pembrolizumab Induces Comparable OS, Fewer AEs in Advanced GEJ Cancer

Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.

Ribociclib Improves Survival by Nearly 30% for Premenopausal Women With Advanced Breast Cancer

Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.

Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Dr. Agarwal on the TALAPRO-2 Trial in mCRPC

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.

ASCO 2019: Oncology Leaders Select Top Studies

Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.

Entrectinib Achieves Strong Responses in Pediatric Cancers, Including CNS Tumors

Entrectinib induced objective responses in 100% of pediatric patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions or mutations.

Pediatric Precision Medicine Approach Proven Possible in Pediatric MATCH Trial

About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.

Lower-Dose Chemotherapy Regimen Benefits Elderly, Frail Patients with Gastroesophageal Cancer

A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.

Lenalidomide Reduces Risk for Smoldering Multiple Myeloma Progression

In patients with smoldering multiple myeloma, lenalidomide induced a 72% reduction in the risk for progression to symptomatic disease at 3 years.

Low-Fat Diet Could Reduce Risk of Death From Breast Cancer

Women who eat a balanced, low-fat diet and daily portions of vegetables, fruit, and grains have a 21% lower risk of dying from breast cancer.

Atezolizumab Regimen Improves OS After TKI Failure in EGFR+ NSCLC

Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.

Dr. Reinmuth on Findings from the MYSTIC Study

Niels Reinmuth, MD, PhD, discusses the results of the MYSTIC study, which evaluated first-line durvalumab plus tremelimumab versus platinum-based chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLC

James Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.

Mok Provides Pembrolizumab Update, Next Steps With Immunotherapy in NSCLC

Tony Mok, MD, discusses the KEYNOTE-042 trial and the implications of its findings, and sheds light on the evolving role of immunotherapy in non–small cell lung cancer.

Nivolumab/Ipilimumab Falls Short as Maintenance Therapy in SCLC

No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.

Ramalingam Discusses Osimertinib Efficacy and the Journey to Overcome Acquired Resistance

Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.

Update Further Supports Osimertinib in Frontline EGFR+ NSCLC

Final results from 2 phase I expansion cohorts of frontline osimertinib (Tagrisso) presented at the 2019 European Lung Cancer Congress confirmed the efficacy of the third-generation TKI in patients with EGFR-positive non­–small cell lung cancer.

Dr. Reck on the Rationale of the Impower150 Study

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

Dr. Paz-Ares on Entrectinib in NTRK Fusion-Positive NSCLC

Luis G. Paz-Ares, MD, PhD, chief physician at the Hospital Universitario Doce De Octubre, discusses an integrated analysis of patients with NTRK fusion–positive non–small-cell lung cancer enrolled in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, which evaluated the safety and efficacy of entrectinib in patients with solid tumors.

Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

PD-L1 Expression Does Not Impact QoL With Durvalumab in NSCLC

Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.

Subsequent Immunotherapy in Control Arm Confounds Frontline Durvalumab Data in NSCLC

The initial overall survival analysis of the phase III MYSTIC trial of first-line durvalumab (Imfinzi) alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer, may have been confounded by high rates of post-study immunotherapy given in the control arm.

Dr. Passaro on Clinical Factors Linked With Improved Outcomes to ALK Inhibitors in NSCLC

Antonio Passaro, MD, PhD, of the Division of Thoracic Oncology, European Institute of Oncology, discusses a study that sought to determine the factors that have an impact on 5-year survival among patients treated for metastatic non–small cell lung cancer using ALK TKIs.

Updated Data Continue to Showcase Efficacy of Larotrectinib, Entrectinib in NSCLC

Larotrectinib showcased an overall response rate of 71% in patients with non–small cell lung cancer harboring NTRK gene fusions.